CPA
RPRX icon

Capital Performance Advisors’s Royalty Pharma RPRX Stock Holding History

Capital Performance Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43
Closed -$1.22K – 2158
2024
Q3 		$1.22K Buy
+43
New +$1.19K ﹤0.01% 1811

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's RPRX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 43 shares — an estimated $1.22K sold.

Capital Performance Advisors first reported a position in RPRX in Q3 2024 and held it in 1 quarter. The position peaked at $1.22K in Q3 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 43 Royalty Pharma shares in Q4 2024, an estimated $1.22K.
  • Capital Performance Advisors first reported a position in Royalty Pharma in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Royalty Pharma position peaked at $1.22K in Q3 2024.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.